Multiple Myeloma Treatment at Karolinska University Hospital

Multiple Myeloma Treatment at Karolinska University Hospital provides specialist hematology care for patients diagnosed with multiple myeloma and related plasma cell disorders. Treatment planning is individualized according to disease characteristics, laboratory and imaging findings, previous treatment, overall health, kidney and bone status, and the patient's specific clinical needs.

Price

Price on Request

Why Price on Request?

The cost of multiple myeloma treatment varies depending on the disease status, diagnostic investigations, medications, treatment combinations, hospitalization requirements, supportive care, and follow-up needs. A personalized cost estimate can be provided after appropriate medical assessment and review of the patient's records.

Complete Description

What Is Multiple Myeloma?

Multiple myeloma is a cancer of plasma cells, a type of blood cell involved in producing antibodies. Abnormal plasma cells can accumulate in the bone marrow and may affect blood counts, bones, kidneys, and other organs.

Specialist hematology assessment helps determine the extent of disease and guide an individualized treatment strategy.

Multiple Myeloma Diagnosis

Diagnosis may involve blood and urine testing, bone marrow examination, imaging studies, and other investigations.

The medical team may assess abnormal proteins, blood cell counts, kidney function, calcium levels, and other findings relevant to the diagnosis.

Disease Assessment and Staging

Patients may undergo further evaluation to determine disease activity and risk characteristics.

Laboratory results, imaging findings, bone marrow information, and other clinical factors can help guide treatment selection and monitoring.

Initial Myeloma Treatment

Treatment for newly diagnosed multiple myeloma may involve combinations of medicines selected according to disease characteristics and the patient's overall health.

The treatment approach may include targeted medicines, immunomodulatory therapies, corticosteroids, chemotherapy, or other systemic treatments when clinically appropriate.

Targeted and Systemic Therapies

Several medicines may be used to target abnormal plasma cells or interfere with their growth and survival.

Treatment combinations are selected according to the patient's diagnosis, previous treatment, response, and individual medical requirements.

Immunotherapy

Selected patients may be considered for immune-based treatments depending on the characteristics of their multiple myeloma and previous therapies.

Specialist assessment is required to determine suitability and the appropriate treatment approach.

Stem Cell Transplantation

Autologous stem cell transplantation may be considered for selected patients with multiple myeloma who are medically suitable.

Eligibility depends on factors such as age, overall health, disease status, previous treatment, and the patient's ability to undergo intensive therapy.

Relapsed or Refractory Multiple Myeloma

Multiple myeloma may return or become less responsive to previous treatment.

Patients with relapsed or refractory disease can undergo specialist reassessment to determine whether alternative medicines, combination therapies, immunotherapy, or other treatment approaches may be appropriate.

Bone Health Management

Multiple myeloma can affect bone strength and increase the risk of bone-related complications.

Depending on the patient's condition, management may include assessment of bone health, imaging, pain management, and medicines intended to reduce complications associated with bone disease.

Kidney Function Monitoring

Multiple myeloma can affect kidney function in some patients.

Kidney function, fluid balance, calcium levels, and other relevant laboratory findings may be monitored during treatment, with management adjusted according to the patient's clinical condition.

Anemia and Blood Count Management

Abnormal plasma cells can interfere with normal blood cell production and may contribute to anemia or other blood count abnormalities.

Regular blood testing helps monitor these changes and identify the need for appropriate supportive management.

Treatment Monitoring

Regular laboratory testing, imaging, and clinical assessments may be used to evaluate treatment response and monitor potential complications.

Treatment can be adjusted according to disease response, laboratory findings, symptoms, and other clinical factors.

Supportive Care

Supportive care may include management of pain, anemia, infection risk, bone complications, kidney-related concerns, and treatment-related side effects.

The type and extent of supportive care depend on the patient's individual needs.

Multidisciplinary Care

Multiple myeloma management may involve hematologists, laboratory specialists, radiologists, transplant specialists, nephrologists, orthopedic specialists, pharmacists, nurses, and other healthcare professionals when appropriate.

Coordinated care can help address the different health concerns associated with the disease.

Second Opinion

Patients who have received a multiple myeloma diagnosis or treatment recommendation may seek a specialist second opinion.

Review of bone marrow findings, laboratory results, imaging, pathology, previous treatment, and other medical records can help provide an additional clinical perspective.

International Patient Care

International patients may be considered for multiple myeloma assessment and treatment subject to applicable eligibility, referral, appointment, and hospital requirements.

Previous laboratory reports, bone marrow results, imaging studies, treatment history, medication information, and medical summaries may be requested for specialist review.

Benefits of Multiple Myeloma Treatment

• Specialist hematology assessment

• Individualized multiple myeloma treatment planning

• Evaluation of disease activity and risk characteristics

• Access to systemic and targeted treatment approaches

• Assessment for immunotherapy when appropriate

• Evaluation for stem cell transplantation

• Monitoring of kidney and bone health

• Management of treatment-related and disease-related complications

Why Choose Karolinska University Hospital?

Karolinska University Hospital provides specialist hematology care within an academic healthcare environment. Patients with multiple myeloma may benefit from multidisciplinary expertise, detailed diagnostic assessment, individualized treatment planning, and coordinated monitoring throughout treatment.

Cost & Price on Request

The overall cost depends on the patient's disease characteristics, diagnostic investigations, treatment medicines, transplant requirements when applicable, supportive care, hospitalization, and follow-up.

Because treatment requirements vary between patients, this service is offered at Price on Request following appropriate medical review.

Frequently Asked Questions

What is multiple myeloma?

Multiple myeloma is a cancer affecting plasma cells in the bone marrow. It can affect blood counts, bones, kidney function, and other aspects of health.

What treatments may be used for multiple myeloma?

Treatment may include combinations of systemic medicines, targeted therapies, immunomodulatory treatments, corticosteroids, immunotherapy, and stem cell transplantation for selected patients.

Is stem cell transplantation available for multiple myeloma?

Stem cell transplantation may be considered for medically suitable patients. Eligibility depends on disease characteristics, overall health, previous treatment, and other clinical factors.

Can multiple myeloma be treated if it returns?

Yes. Relapsed or refractory multiple myeloma can be reassessed, and additional treatment options may be considered according to the patient's disease status and previous therapies.

Can international patients receive multiple myeloma treatment at Karolinska University Hospital?

International patients may be considered subject to applicable eligibility, referral, appointment, and hospital requirements. Medical records and previous diagnostic and treatment information may be required for assessment.

Product Details

Product Name: Multiple Myeloma Treatment at Karolinska University Hospital
Hospital: Karolinska University Hospital
Brand: Karolinska University Hospital
Country: Sweden
Location: Stockholm, Sweden
Specialty: Hematology & Blood Disorders
Service Type: Multiple Myeloma Treatment
Customer-Facing Price: Price on Request
International Patients: Subject to applicable eligibility and appointment requirements